Mohamed Asmaa Hussein, Elfeky Mariem A, Elshorbagy Shereen, Hefzi Nabila, Oraby Tamer, Abdelhady Waleed A, Eldein Mahmoud Sharaf, Embaby Ahmed, Oraby Ehab M
Department of Pathology, Zagazig University Faculty of Medicine, Zagazig, Egypt.
Department of Medical Oncology, Faculty of Medicine, Zagazig University Zagazig, Egypt.
Contemp Oncol (Pozn). 2022;26(1):49-58. doi: 10.5114/wo.2022.115675. Epub 2022 Mar 30.
Diffuse large B-cell non- Hodgkin lymphoma (DLBCL) is the largest common category of adult lymphoma. Recurrence and treatment resistance occurs in one-third of cases, triggering them to the progressive stage of DLBCL after treatment. Detection of novel predictive and prognostic biomarkers leads to improvement of its treatment and prognosis.
To assess the prognostic roles of protein expression of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) in tissues of DLBCL patients.
In the current study we included tissues from 100 cases of DLBCL. For immunohistochemistry, tissues were stained with MYD88 and TBLR1. We followed patients for about 3 years, and then we correlated their expression with clinicopathological and prognostic parameters.
Higher MYD88 and TBLR1 expressions were associated with presence of B symptoms, fever, night sweat, advanced stage, bone marrow involvement and bulky nodal size, presence of extra-nodal extension, unfavourable relapse-free survival, and unfavourable overall survival rates ( < 0.001).
overexpression of MYD88 and TBLR1 expression was present in DLBCL patients and was associated with unfavourable clinicopathological and prognostic parameters.
弥漫性大B细胞非霍奇金淋巴瘤（DLBCL）是成人淋巴瘤中最常见的类型。三分之一的病例会出现复发和治疗抵抗，导致其在治疗后进入DLBCL的进展期。检测新的预测和预后生物标志物可改善其治疗和预后。
评估髓样分化因子88（MYD88）和转导素（β）样受体1（TBLR1）蛋白表达在DLBCL患者组织中的预后作用。
在本研究中，我们纳入了100例DLBCL患者的组织。对于免疫组织化学，组织用MYD88和TBLR1进行染色。我们对患者进行了约3年的随访，然后将它们的表达与临床病理和预后参数进行关联。
较高的MYD88和TBLR1表达与B症状、发热、盗汗、晚期、骨髓受累和淋巴结肿大、结外扩展的存在、无复发生存不良和总生存率不良相关（<0.001）。
MYD88过表达和TBLR1表达存在于DLBCL患者中，并与不良的临床病理和预后参数相关。
